MS
ACET icon

Maven Securities’s Adicet Bio ACET Stock Holding History

Maven Securities’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,250
Closed -$263K – 390
2025
Q4 		$263K Buy
+31,250
New +$345K 0.01% 452
2021
Q2 		– Sell
-2,312
Closed -$489K – 1013
2021
Q1 		$489K Buy
+2,312
New +$531K 0.02% 682

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Maven Securities's ACET Position: Q1 2026 in Review

Maven Securities sold out of Adicet Bio (ACET) in Q1 2026, closing a stake of 31,250 shares — an estimated $263K sold.

Maven Securities first reported a position in ACET in Q1 2021 and held it in 2 quarters. The position peaked at $489K in Q1 2021. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Maven Securities reported no remaining Adicet Bio position as of Q1 2026 after selling out during the quarter.
  • Maven Securities sold 31,250 Adicet Bio shares in Q1 2026, an estimated $263K.
  • Maven Securities first reported a position in Adicet Bio in Q1 2021 and held it in 2 quarters.
  • Maven Securities's Adicet Bio position peaked at $489K in Q1 2021.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.